After follow up of seven TET2 mutant individuals for at least 5 years, one developed evidence of a haematological malignancy: a JAK2V617F mutant myeloproliferative neoplasm (MPN) (Busque et al., 2012). This evidence concerns the gene TET2 and myeloproliferative neoplasm.